复星医药:关于控股子公司药品获临床试验批准的公告

复星医药:关于控股子公司药品获临床试验批准的公告
View on original source
Category: Health
Share
Archive
Like
证券日报网讯 9月8日,复星医药发布公告称,公司控股子公司上海复星医药产业发展有限公司近日收到国家药品监督管理局关于同意FXS5626片(原项目代号:AC-201)用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。

(0)Comments

 

A note on cookies

Newshunt uses essential cookies to keep you signed in and to remember your language and country, so the site works the way you expect. With your permission, we'd also like to use analytics cookies to understand how people use Newshunt and improve it over time.

Accepting only affects analytics. To learn more, view our Privacy Policy or Terms & Conditions.